...
mtnb-img

Matinas BioPharma Holdings Inc, Common Stock

MTNB

ASQ

$0.5666

-$0.03

(-5.07%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.01M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
37.32K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.73
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.5 L
$18.49 H
$0.5666

About Matinas BioPharma Holdings Inc, Common Stock

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMTNBSectorS&P500
1-Week Return-2.48%-3.35%-2.97%
1-Month Return0.28%-3.49%-0.66%
3-Month Return-84.97%-12.6%2.71%
6-Month Return-92.74%-6.91%7.21%
1-Year Return-95.11%1.19%23.04%
3-Year Return-98.92%-0.21%28.43%
5-Year Return-99.35%33.09%82.88%
10-Year Return-97.54%93.55%184.63%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue90.00K158.33K33.33K3.19M1.10M[{"date":"2019-12-31","value":2.82,"profit":true},{"date":"2020-12-31","value":4.97,"profit":true},{"date":"2021-12-31","value":1.05,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":34.38,"profit":true}]
Cost of Revenue11.23M14.36M781.49K16.68M14.49M[{"date":"2019-12-31","value":67.36,"profit":true},{"date":"2020-12-31","value":86.09,"profit":true},{"date":"2021-12-31","value":4.69,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":86.87,"profit":true}]
Gross Profit(11.14M)(14.20M)(748.16K)(13.49M)(13.39M)[{"date":"2019-12-31","value":-1114454800,"profit":false},{"date":"2020-12-31","value":-1420058500,"profit":false},{"date":"2021-12-31","value":-74815800,"profit":false},{"date":"2022-12-31","value":-1349000000,"profit":false},{"date":"2023-12-31","value":-1339300000,"profit":false}]
Gross Margin(12382.83%)(8968.81%)(2244.50%)(423.15%)(1221.99%)[{"date":"2019-12-31","value":-12382.83,"profit":false},{"date":"2020-12-31","value":-8968.81,"profit":false},{"date":"2021-12-31","value":-2244.5,"profit":false},{"date":"2022-12-31","value":-423.15,"profit":false},{"date":"2023-12-31","value":-1221.99,"profit":false}]
Operating Expenses19.01M24.36M24.77M11.10M24.86M[{"date":"2019-12-31","value":76.47,"profit":true},{"date":"2020-12-31","value":98,"profit":true},{"date":"2021-12-31","value":99.62,"profit":true},{"date":"2022-12-31","value":44.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(18.92M)(24.21M)(24.73M)(24.59M)(23.77M)[{"date":"2019-12-31","value":-1892100000,"profit":false},{"date":"2020-12-31","value":-2420655200,"profit":false},{"date":"2021-12-31","value":-2473475500,"profit":false},{"date":"2022-12-31","value":-2459000000,"profit":false},{"date":"2023-12-31","value":-2376600000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(17.37M)(22.45M)(23.28M)(21.00M)(22.94M)[{"date":"2019-12-31","value":-1737300000,"profit":false},{"date":"2020-12-31","value":-2244683800,"profit":false},{"date":"2021-12-31","value":-2328341500,"profit":false},{"date":"2022-12-31","value":-2099700000,"profit":false},{"date":"2023-12-31","value":-2294200000,"profit":false}]
Income Taxes(1.79M)(1.85M)(2.11M)(7.98M)773.11K[{"date":"2019-12-31","value":-231.25,"profit":false},{"date":"2020-12-31","value":-239.02,"profit":false},{"date":"2021-12-31","value":-272.92,"profit":false},{"date":"2022-12-31","value":-1032.46,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(17.37M)(22.45M)(23.28M)(21.00M)(21.26M)[{"date":"2019-12-31","value":-1737265100,"profit":false},{"date":"2020-12-31","value":-2244683800,"profit":false},{"date":"2021-12-31","value":-2328341500,"profit":false},{"date":"2022-12-31","value":-2099700000,"profit":false},{"date":"2023-12-31","value":-2126200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(15.59M)(20.60M)(21.17M)(13.02M)(22.94M)[{"date":"2019-12-31","value":-1558518400,"profit":false},{"date":"2020-12-31","value":-2059896200,"profit":false},{"date":"2021-12-31","value":-2117345400,"profit":false},{"date":"2022-12-31","value":-1301500000,"profit":false},{"date":"2023-12-31","value":-2294200000,"profit":false}]
EPS (Diluted)(0.14)(0.12)(0.11)(0.11)(0.11)[{"date":"2019-12-31","value":-14,"profit":false},{"date":"2020-12-31","value":-12,"profit":false},{"date":"2021-12-31","value":-11,"profit":false},{"date":"2022-12-31","value":-11,"profit":false},{"date":"2023-12-31","value":-11,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MTNB
Cash Ratio 5.08
Current Ratio 5.53

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MTNB
ROA (LTM) -50.87%
ROE (LTM) -97.59%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MTNB
Debt Ratio Lower is generally better. Negative is bad. 0.23
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.77

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MTNB
Trailing PE NM
Forward PE NM
P/S (TTM) 46.50
P/B 0.19
Price/FCF NM
EV/R 37.20
EV/Ebitda NM
PEG NM

FAQs

What is Matinas BioPharma Holdings Inc share price today?

Matinas BioPharma Holdings Inc (MTNB) share price today is $0.5666

Can Indians buy Matinas BioPharma Holdings Inc shares?

Yes, Indians can buy shares of Matinas BioPharma Holdings Inc (MTNB) on Vested. To buy Matinas BioPharma Holdings Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MTNB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Matinas BioPharma Holdings Inc be purchased?

Yes, you can purchase fractional shares of Matinas BioPharma Holdings Inc (MTNB) via the Vested app. You can start investing in Matinas BioPharma Holdings Inc (MTNB) with a minimum investment of $1.

How to invest in Matinas BioPharma Holdings Inc shares from India?

You can invest in shares of Matinas BioPharma Holdings Inc (MTNB) via Vested in three simple steps:

  • Click on Sign Up or Invest in MTNB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Matinas BioPharma Holdings Inc shares
What is Matinas BioPharma Holdings Inc 52-week high and low stock price?

The 52-week high price of Matinas BioPharma Holdings Inc (MTNB) is $18.49. The 52-week low price of Matinas BioPharma Holdings Inc (MTNB) is $0.5.

What is Matinas BioPharma Holdings Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Matinas BioPharma Holdings Inc (MTNB) is

What is Matinas BioPharma Holdings Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Matinas BioPharma Holdings Inc (MTNB) is 0.19

What is Matinas BioPharma Holdings Inc dividend yield?

The dividend yield of Matinas BioPharma Holdings Inc (MTNB) is 0.00%

What is the Market Cap of Matinas BioPharma Holdings Inc?

The market capitalization of Matinas BioPharma Holdings Inc (MTNB) is $3.01M

What is Matinas BioPharma Holdings Inc’s stock symbol?

The stock symbol (or ticker) of Matinas BioPharma Holdings Inc is MTNB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top